Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,034 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LIONS PREY: A New Logistic Scoring System for the Prediction of Malignant Pulmonary Nodules.
Doerr F, Giese A, Höpker K, Menghesha H, Schlachtenberger G, Grapatsas K, Baldes N, Baldus CJ, Hagmeyer L, Fallouh H, Pinto Dos Santos D, Bender EM, Quaas A, Heldwein M, Wahlers T, Hautzel H, Darwiche K, Taube C, Schuler M, Hekmat K, Bölükbas S. Doerr F, et al. Among authors: schuler m. Cancers (Basel). 2024 Feb 9;16(4):729. doi: 10.3390/cancers16040729. Cancers (Basel). 2024. PMID: 38398120 Free PMC article.
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Reis H, Metzenmacher M, Goetz M, Savvidou N, Darwiche K, Aigner C, Herold T, Eberhardt WE, Skiba C, Hense J, Virchow I, Westerwick D, Bogner S, Ting S, Kasper S, Stuschke M, Nensa F, Herrmann K, Hager T, Schmid KW, Schuler M, Wiesweg M. Reis H, et al. Among authors: schuler m. Clin Lung Cancer. 2018 Jul;19(4):e441-e463. doi: 10.1016/j.cllc.2018.03.010. Epub 2018 Mar 17. Clin Lung Cancer. 2018. PMID: 29631966
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma.
Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F. Oezkan F, et al. Among authors: schuler m. Clin Lung Cancer. 2018 Nov;19(6):e879-e884. doi: 10.1016/j.cllc.2018.08.016. Epub 2018 Aug 22. Clin Lung Cancer. 2018. PMID: 30206042
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, Krebs B, Metzenmacher M, Theegarten D, Gauler T, Jöckel KH, Darwiche K, Aigner C, Stuschke M, Eberhardt WE. Guberina N, et al. Among authors: schuler m. Eur J Cancer. 2020 Oct;138:156-168. doi: 10.1016/j.ejca.2020.07.025. Epub 2020 Sep 2. Eur J Cancer. 2020. PMID: 32889370
Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.
Guberina M, Darwiche K, Hautzel H, Ploenes T, Pöttgen C, Guberina N, Herrmann K, Umutlu L, Wetter A, Theegarten D, Aigner C, Eberhardt WEE, Schuler M, Karpf-Wissel R, Stuschke M. Guberina M, et al. Among authors: schuler m. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2894-2903. doi: 10.1007/s00259-021-05204-7. Epub 2021 Feb 5. Eur J Nucl Med Mol Imaging. 2021. PMID: 33547554 Free PMC article.
Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.
Metzenmacher M, Goetz M, Herold T, Stuschke M, Aigner C, Darwiche K, Eberhardt WE, Schuler M, Wiesweg M. Metzenmacher M, et al. Among authors: schuler m. Clin Lung Cancer. 2021 Sep;22(5):e668-e672. doi: 10.1016/j.cllc.2020.11.008. Epub 2020 Dec 2. Clin Lung Cancer. 2021. PMID: 33551244 No abstract available.
1,034 results